Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt
The 20th anniversary of the German CLL Study Group and the importance of collaboration
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
Understanding why CLL patients stop responding to treatment, and options for salvage therapies
Homeless tumour cells in CLL